Modelling the cost effectiveness of treatments for parkinsons disease: A methodological review

PharmacoEconomics

Volumn 29, Issue 12, 2011, Pages 1025-1049

  Dams, Judith ^a   Bornschein, Bernhard ^b   Reese, Jens Peter ^a   Conrads Frank, Annette ^b   Oertel, Wolfgang H ^a   Siebert, Uwe ^b,c   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiparkinsonians; Cost effectiveness; Modelling; Parkinsons disease.

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; ENTACAPONE; IOFLUPANE I 123; LEVODOPA; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINROLE; SELEGILINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; COCHRANE LIBRARY; COMORBIDITY; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SCREENING; DYSKINESIA; ECONOMIC EVALUATION; EMBASE; ESSENTIAL TREMOR; HIDDEN MARKOV MODEL; HOEHN AND YAHR SCALE; HUMAN; LABORATORY DIAGNOSIS; MEDLINE; MODEL; NEUROSURGERY; PARKINSON DISEASE; PARKINSONISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SCISEARCH; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOTAL QUALITY MANAGEMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; PARKINSON DISEASE;

EID: 81255210951     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587110-000000000-00000     Document Type: Review

References (79)

1. Hoehn MM. The natural history of Parkinsons disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10 (2): 331-9
2. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinsons disease in a Scottish city. BMJ 1986; 292 (6519): 534-6
3. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann. Neurol. 1984; 16 (3): 278-82 (Pubitemid 14041762)
4. Sutcliffe RL, Meara JR. Parkinsons disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995; 92: 443-50
5. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinsons disease. Mov. Disord. 2003; 18 (1): 19-31 (Pubitemid 36150204)
6. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinsons disease? JNeurol Neurosurg Psychiatry 2000; 69 (3): 308-12 (Pubitemid 30636233)
7. Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, et al., editors. Neurological disorders: course and treatment. San Diego (CA): Academic Press, 2003
8. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinsons disease (2001): treatment guidelines. Neurology 2001; 56 (11 Suppl. 5): S1-88
9. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinsons disease: An evidence based assessment. Lancet 2002; 359 (9317): 1589-98 (Pubitemid 34621128)
10. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: An expert consensus and review of key issues. Arch. Neurol. 2011; 68: 165
11. Kluger BM, Klepitskaya O, Okun MS. Surgical treatment of movement disorders. Neurol Clin 2009; 27: 633-77
12. Puig-Junoy J, Puig Peiro R. Review of the economic evidence on the use of deep brain stimulation in late stage Parkinsons disease. Neurologia 2009; 24 (4): 220-9
13. Eggert KM, Reese JP, Oertel WH, et al. Cost effectiveness of pharmacotherapies in early Parkinsons disease. CNS Drugs 2008; 22 (10): 841-60
14. Siebert U, Bornschein B, Walbert T, et al. Systematic assessment of decision models in Parkinsons disease. Value Health 2004; 7 (5): 610-26 (Pubitemid 39390841)
15. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6 (1): 9-17 (Pubitemid 36228345)
16. Nuijten MJ. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Pharmacoeconomics 2004; 22 (12): 759-69 (Pubitemid 39158996)
17. Nuijten MJ, Kosa J, Engelfriet P. Modeling the costeffectiveness and budgetary impact for subpopulations. Eur J Health Econ 2003; 4 (2): 70-8 (Pubitemid 36841514)
18. Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decisionanalytic modelling techniques. Pharmacoeconomics 2002; 20 (12): 855-67 (Pubitemid 35216498)
19. Nuijten MJ, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003; 21 (13): 941-50 (Pubitemid 37222568)
20. van den Hout A,Matthews FE. Estimating dementia-free life expectancy for Parkinsons patients using Bayesian inference and microsimulation. Biostatistics 2009; 10 (4): 729-43
21. Drummond MF, O'Brien B, Stoddard GL, et al. Methods for the economic evaluation of health care programs. New York: Oxford University Press, 1997
22. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
23. Siebert U, Behrend C, Mühlberger N, et al. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ö konomischer Evaluationsstudien in Deutschland. In: Leidel R, Graf von der Schulenburg JM, Wasem J, editors. Approaches and methods of economic evaluation in health care: An international perspective [in German]. Baden- Baden: Nomos Verlagsgesellschaft, 1999: 156-70
24. Lindgren P, Jonsson B, Duchane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. Eur J Health Econ 2003; 4 (1): 37-42 (Pubitemid 36457055)
25. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinsons disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23-30 (Pubitemid 28051035)
26. Hagell P, Nordling S, Reimer J, et al. Resource use and costs in a Swedish cohort of patients with Parkinsons disease. Mov. Disord. 2002 Nov; 17 (6): 1213-20 (Pubitemid 36041335)
27. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinsons disease: An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14 (3): 299-312 (Pubitemid 28416933)
28. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinsons disease. Pharmacoeconomics 1999; 16 (1): 59-69 (Pubitemid 29330472)
29. Smala AM, Spottke EA, Machat O, et al. Cabergoline versus levodopa monotherapy: A decision analysis. Mov. Disord. 2003; 18 (8): 898-905 (Pubitemid 37021164)
30. Di Rocco A, Molinari SP, Kollmeier B, et al. Parkinsons disease: progression and mortality in the L-DOPAera. Adv Neurol 1996; 69: 3-11
31. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinsons disease in Germany. Pharmacoeconomics 2005; 23: 817-36 (Pubitemid 41420428)
32. Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinsons disease in Finland. Ann Pharmacother 2006; 40 (4): 651-7
33. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005; 365 (9463): 947-54
34. Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinsons disease. Qual Life Res 2000; 9 (7): 819-27 (Pubitemid 32209796)
35. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9 (3): 163-8 (Pubitemid 36173566)
36. Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinsons disease in the UK setting: An economicMarkov model evaluation. Drugs Aging 2009; 26 (9): 791-801
37. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch. Neurol. 2002; 59 (12): 1937-43
38. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004; 61 (4): 561-6
39. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch. Neurol. 2004; 61 (7): 1044-53 (Pubitemid 38915945)
40. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinsons disease patients. Ann. Neurol. 1997; 42: 747-55
41. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinsons disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342 (20): 1484-91 (Pubitemid 30318272)
42. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinsons disease: A research survey in the United Kingdom. Mov. Disord. 2003; 18 (10): 1139-45 (Pubitemid 37336937)
43. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinsons disease patients with wearing-off. Curr Med Res Opin 2005; 21 (7): 1005-14 (Pubitemid 41032689)
44. Schrag A, Jahanshahi M, Quinn N. How does Parkinsons disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord. 2000; 15 (6): 1112-8
45. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. NOMECOMT Study Group. Neurology 1998; 51 (5): 1309-14 (Pubitemid 28520549)
46. UK Office for National Statistics. Mortality rates [online]. Available from URL: http://www.statistics.gov.uk [Accessed 2010 Mar 1]
47. Kristiansen IS, Bingefors K, Nyholm D, et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinsons disease in Sweden: An exploratory study. Appl Health Econ Health Policy 2009; 7 (3): 167-80
48. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64 (2): 216-23
49. Goulionis JE, Vozikis A. Medical decision making for patients with Parkinson disease under average cost criterion. Aust New Zealand Health Policy 2009; 6: 15
50. Hjelmgren J, Ghatnekar O, Reimer J, et al. Estimating the value of novel interventions for Parkinsons disease: An early decision-making model with application to dopamine cell replacement. Parkinsonism Relat Disord 2006; 12 (7): 443-52 (Pubitemid 44416294)
51. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinsons disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67 (3): 300-7 (Pubitemid 29392588)
52. Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinsons disease. J Neurol Neurosurg Psychiatry 2000; 69 (1): 67-73 (Pubitemid 30410417)
53. Lindvall OF, Hagell P. Status of neural repair clinical trials in brain diseases. In: Selzer ME, Clarke S, Cohen LG, et al., editors. Textbook of neural repair and rehabilitation: neural repair and plasticity. Vol. 1. Cambridge: Cambridge University Press, 2006: 615-31
54. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinsons disease. Nat Neurosci 2002; 5 (7): 627-8 (Pubitemid 34742975)
55. Antonini A, Berto P, Lopatriello S, et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinsons disease in Italy. MovDisord 2008; 23 (15): 2202-9
56. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FPCIT study group. Mov. Disord. 2000; 15 (3): 503-10 (Pubitemid 30333223)
57. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinsons disease. Age Ageing 1999; 28: 99-102 (Pubitemid 29161211)
58. Van Laere K, Everaert L, Annemans L, et al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35 (7): 1367-76
59. Hughes AJ, Daniel SE, Kilford L, et al. The accuracy of clinical diagnosis of idiopathic Parkinsons disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4
60. Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54 (11 Suppl. 4): S21-5 (Pubitemid 30390611)
61. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: A prospective study. Can J Neurol Sci 1991; 18: 275-8
62. Dodel RC, Hö ffken H, Mö ller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinsons disease: A decision-analytic approach.Mov. Disord. 2003; 18 Suppl. 7: S52-62 (Pubitemid 37336929)
63. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinsons disease: A clinicopathologic study. 1992. Neurology 2001; 57 (10 Suppl. 3): S34-8
64. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70 (Pubitemid 34279780)
65. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinsons disease. Neurology 2001; 57 (8): 1497-9 (Pubitemid 32995738)
66. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356 (1): 29-38 (Pubitemid 46041751)
67. Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinsons disease: A Markov process analysis. Value Health 2001; 4 (4): 316-28 (Pubitemid 32756816)
68. Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinsons disease with entacapone in the United States. Pharmacoeconomics 2002; 20 (9): 617-28
69. Herlofson K, Lie SA, Arsland D, et al. Mortality and Parkinson disease: A community based study. Neurology 2004; 62 (6): 937-42 (Pubitemid 38435782)
70. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284 (15): 1931-8
71. Linna M, Taimela E, Apajasalo M, et al. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinsons disease. Expert Rev Pharmacoecon Outcomes Res 2002; 2 (2): 91-7 (Pubitemid 34649779)
72. Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and nonfluctuating patients with Parkinsons disease: A randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74 (8): 1071-9
73. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinsons disease: long-term experience. Acta Neurol Scand 2001; 104 (6): 343-8 (Pubitemid 33107378)
74. Ministry of Health. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariff GU n 216 of 14/11/1996: DM 22/07/1996
75. Winter Y, von Campenhausen S, Arend M, et al. Healthrelated quality of life and its determinants in Parkinsons disease: Results of an Italian cohort study. Parkinsonism Relat Disord; 17 (4): 265-9
76. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003; 183: 498-506 (Pubitemid 37533195)
77. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332 (7543): 699-703
78. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
79. Institute for Quality and Efficiency in Health Care. Working Paper on Modelling in health economic evaluations. Cologne: IQWiG, 2009 [online]. Available from URL: https://www.iqwig.de/download/Working-Paper-Modelling.pdf [Accessed 2010 Jun 21]